Fresenius Kabi Caring For Life
For US and Puerto Rico Healthcare Professionals
For US and Puerto Rico Healthcare Professionals

FAQs

Show All

Find answers to your most frequently asked questions below.

What are Kabiven and Perikabiven?

Kabiven for central infusion and Perikabiven for peripheral or central infusion are parenteral nutrition (PN) in a three-chamber bag. They efficiently deliver amino acids, electrolytes, dextrose, and lipids in volumes and concentrations that cover the requirements of most PN patients.

What is the difference between Kabiven and Perikabiven?

Kabiven is a parenteral nutrition solution with an osmolarity of 1060 mOsm/L, and thus must be infused only via the central venous system such as the superior vena cava. Perikabiven is a parenteral nutrition solution with an osmolarity of 750 mOsm/L, and thus is suitable for either peripheral or central venous infusion.

What are the advantages of the three-chamber bag for clinicians and patients?

The Kabiven and Perikabiven three-chamber bags efficiently deliver three macronutrients plus electrolytes in volumes and concentrations that meet the needs of most PN patients. Kabiven and Perikabiven can help support PN safety and minimize the risk of contamination.1 They streamline the delivery of nutrition therapy to simplify: calculations for dietitians, compounding for pharmacists, prescription writing for physicians, and administration for nurses.

How can Kabiven and Perikabiven help clinicians during drug shortages?

Kabiven and Perikabiven contain amino acids, dextrose, lipids, and electrolytes, which have all been on drug shortage at least one time in the last few years. Kabiven and Perikabiven are a safe option to meet the patient's nutritional needs when macro or micronutrients are on shortage.

Is Kabiven appropriate for a range of patients?

Kabiven and Perikabiven are available in several volumes to meet the nutrient needs of most PN patients.

What sizes of Kabiven and Perikabiven are offered?

Kabiven is available in four sizes: 1026 mL, 1540 mL, 2053 mL, and 2566 mL. Perikabiven is available in three sizes: 1440 mL, 1920 mL, and 2400 mL.

What is the shelf life of Kabiven and Perikabiven?

  • Up to 24 months shelf life at 20–25°C (68–77°F)
  • Use Kabiven immediately after activation. Without additives, the activated Kabiven bag can be stored for up to 7 days under refrigeration [2° to 8° C (36° to 46°F)]. After removal from refrigeration, the activated bag should be used within 48 hours.
  • Once additives are introduced, use Kabiven immediately. If not used immediately, the activated bag with additives may be stored for up to 24 hours at 2–8°C (36–46°F)
  • Perkabiven should be used immediately after mixing and introduction of additives. If not used immediately, the storage time and conditions prior to use should not be longer than 24 hours at 2-8C (36-46F). After removal from storage, the admixture should be infused within 24 hrs.

What are the materials used to manufacture the bag?

The bag is composed of a multi-layer polyolefin film that is non-PVC, non-DEHP, and not made from natural rubber latex.

What size needle should be used to make additions?

Additions should be made by using an 18–23 G needle with a maximum length of 1½ inches. The additive port can be pierced up to 10 times using aseptic technique.

What type of spike/infusion set can be used with the bag?

Use a standard non-vented infusion set with an external spike diameter of 5.5–5.7 mm (according to ISO Number 8536-4). The infusion set should contain or be connected with a 1.2 micron in-line filter.

Where are Kabiven and Perikabiven manufactured?

Kabiven and Perikabiven bags are manufactured by Fresenius Kabi in Uppsala, Sweden, an FDA-licensed European Union production facility. They are manufactured according to FDA current Good Manufacturing Practice (cGMP) regulations.

How can I order Kabiven and Perikabiven?

Orders can be placed by calling customer service at 1-888-386-1300 or by contacting your local Fresenius Kabi Sales Representative.
Reference: 1. Derenski K. Standardize parenteral nutrition using commercial premix. Pharm Purchasing Prod. 2012;1-7.

Kabiven and Perikabiven three-chamber bags must be mixed prior to infusion. For admixing instructions see INSTRUCTIONS FOR USE in the prescribing information.

INDICATIONS AND LIMITATIONS OF USE

  • Kabiven and Perikabiven are each indicated as a source of calories, protein, electrolytes and essential fatty acids for adult patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. Kabiven and Perikabiven may be used to prevent essential fatty acid deficiency or treat negative nitrogen balance in adult patients.
  • Kabiven is indicated for intravenous infusion into a central vein.
  • Perikabiven is indicated for intravenous infusion into a peripheral or central vein.
  • Neither Kabiven nor Perikabiven is recommended for use in pediatric patients < 2 years, including preterm infants because the fixed content of the formulations do not meet the nutritional requirements in this age group.

IMPORTANT SAFETY INFORMATION

WARNING
  • Deaths in preterm infants have been reported in literature.
  • Autopsy findings included intravascular fat accumulation in the lungs.
  • Preterm and low birth weight infants have poor clearance of intravenous lipid emulsion and increased free fatty acid plasma levels following lipid emulsion infusion.

CONTRAINDICATIONS

  • Known hypersensitivity to egg, soybean proteins, peanut proteins, corn or corn products, or to any of the active substances or excipients.
  • Severe hyperlipidemia or severe disorders of lipid metabolism with serum triglycerides >1000 mg/dL.
  • Inborn errors of amino acid metabolism.
  • Cardiopulmonary instability.
  • Hemophagocytic syndrome.

WARNINGS AND PRECAUTIONS

  • Kabiven is hypertonic and may cause vein irritation, vein damage and even thrombosis if infused in a peripheral vein. Only infuse Kabiven into a central vein.
  • Monitor for signs or symptoms of hypersensitivity reactions and discontinue infusion if reactions occur.
  • Monitor patient closely for signs and symptoms of infection, hypertriglyceridemia, hyperglycemia and refeeding complications.
  • Monitor laboratory parameters for alterations in electrolytes, liver and renal impairment, fluid status and coagulation parameters. Adjust rate and dose of Kabiven and Perikabiven according to clinical status.

To report suspected adverse reactions, contact Fresenius Kabi USA, LLC, at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information, including Boxed Warning, for Kabiven and Perikabiven.